Results 251 to 260 of about 113,223 (329)

MyD88 Deficiency Protects Mice From Experimental Autoimmune Encephalomyelitis by Influencing Both Dendritic Cells and T Cells

open access: yesImmunology, EarlyView.
This study investigates the role of MyD88 in dendritic cells (DCs) and T cells during experimental autoimmune encephalomyelitis (EAE). We found that MyD88 is highly expressed in DCs and CD4+ T cells in people with multiple sclerosis, and its deficiency impairs DC maturation, reduces pro‐inflammatory cytokine production, weakens DC–T cell interactions ...
Wen Si   +4 more
wiley   +1 more source

Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis

open access: yesImmunology, EarlyView.
Microbial imbalance, dysbiosis, plays a role in ovarian carcinogenesis by interacting with the immune system and altering inflammatory pathways, notably Th17 pathways. In contrast, eubiosis, characterised by Lactobacillus dominance, protects against infections and maintains hormone metabolism.
Wafa Babay   +4 more
wiley   +1 more source

Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Phoebe Wellmann   +3 more
wiley   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta   +5 more
wiley   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy